Esther Cheng Yin Lee

This inventor holds 11 USPTO granted patents and 3 published patent applications and 5 EPO patents. Top assignee: Pfizer Corporation. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Esther Cheng Yin Lee. Retrieved from https://idiyas.com/inventor/esther-cheng-yin-lee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 11 (Patent Applications = 3)

% Patents Active = 54.5

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 8.7

ph-index = 2

Forward Citations = 12(Granted Patents)

Location History:

Mystic, CT (US) (2013)
Shirley, MA (US) (2014)
Brookline, MA (US) (2015 - 2018)
Newton, MA (US) (2021 - 2024)

Company Filing History:

11 out of 4,489

Pfizer Corporation

patents

Years Active: 2013-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12703696 - Diacylglycerol acyl transferase 2 inhibitors (2026-08-11),

2. 11866425 - Diacylglycerol acyl transferase 2 inhibitors (2024-01-09),

3. 11034678 - Diacylglycerol acyl transferase 2 inhibitors (2021-06-15),

4. 10071992 - Diacylglycerol acyl transferase 2 inhibitors (2018-09-11),

5. 9738626 - Antagonists of prostaglandin EP3 receptor (2017-08-22),

6. 9452999 - Glucagon receptor modulators (2016-09-27),

7. 9394285 - Indole and indazole compounds that activate AMPK (2016-07-19),

8. 9278953 - Antagonists of prostaglandin EP3 receptor (2016-03-08),

9. 9073871 - Glucagon receptor modulators (2015-07-07),

10. 8859591 - Glucagon receptor modulators (2014-10-14),

11. 8507533 - Glucagon receptor modulators (2013-08-13),

Title: **The Innovative Mind of Esther Cheng Yin Lee**

Introduction

Esther Cheng Yin Lee, a distinguished inventor based in Brookline, MA, has made significant contributions to the field of pharmaceutical innovations. With a remarkable portfolio of 10 patents, she is recognized for her groundbreaking work in developing compounds that have the potential to transform treatments for various diseases.

Latest Patents

Among her latest contributions are her patents concerning diacylglycerol acyl transferase 2 (DGAT2) inhibitors. These patents describe compounds of Formula I that inhibit the activity of DGAT2 and outline their applications in treating diseases associated with this enzyme in animals. Such advancements may pave the way for new therapeutic options, showcasing her expertise and commitment to innovation in medicine.

Career Highlights

Esther's career is closely linked with Pfizer Corporation, a leading global biopharmaceutical company. Her role there has allowed her to push the boundaries of scientific research and development, contributing to significant advancements in drug formulation and delivery.

Collaborations

Throughout her career, Esther has worked closely with talented colleagues, including Kentaro Futatsugi and Kevin James Filipski. This collaborative spirit has not only enhanced her own research but has also fostered an environment of creativity and innovation within her team.

Conclusion

Esther Cheng Yin Lee stands out as a prominent figure in the field of pharmaceuticals. Her impressive number of patents and her determination to develop effective treatments highlight her status as a leading inventor. As her work continues to evolve, her contributions are likely to have a lasting impact on healthcare and therapeutic methodologies.

Profile summary based on public USPTO records.